| ID Source | ID |
|---|---|
| PubMed CID | 4879298 |
| CHEMBL ID | 1300370 |
| CHEBI ID | 91926 |
| Synonym |
|---|
| MLS-0258268.0001 , |
| MLS-0258268.0002 |
| MLS001033453 |
| smr000385627 |
| MLS002460482 |
| MLS-0258268.0003 |
| 5'-bromospiro[1,2-dihydro-4,1,2-benzoxadiazine-3,3'-1h-indole]-2'-one |
| CHEMBL1300370 |
| HMS2228I22 |
| HMS3356D21 |
| 5''-bromospiro[1,2-dihydro-4,1,2-benzoxadiazine-3,3''-1h-indole]-2''-one |
| 5''-bromanylspiro[1,2-dihydro-4,1,2-benzoxadiazine-3,3''-1h-indole]-2''-one |
| 5''-bromospiro[1,2-dihydro-4,1,2-benzoxadiazine-3,3''-indoline]-2''-one |
| cid_4879298 |
| 5''-bromo-2''-spiro[1,2-dihydro-4,1,2-benzoxadiazine-3,3''-1h-indole]one |
| bdbm43816 |
| CHEBI:91926 |
| Z57980682 |
| 5'-bromo-2'-spiro[1,2-dihydro-4,1,2-benzoxadiazine-3,3'-1h-indole]one |
| Q27163725 |
| 5'-bromo-1,2-dihydrospiro[benzo[e][1,3,4]oxadiazine-3,3'-indolin]-2'-one |
| Class | Description |
|---|---|
| organonitrogen compound | Any heteroorganic entity containing at least one carbon-nitrogen bond. |
| organooxygen compound | An organochalcogen compound containing at least one carbon-oxygen bond. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 44.6684 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 35.4813 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 37.9330 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
| acid sphingomyelinase | Homo sapiens (human) | Potency | 79.4328 | 14.1254 | 24.0613 | 39.8107 | AID504937 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 28.1838 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| GLS protein | Homo sapiens (human) | Potency | 35.4813 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
| TDP1 protein | Homo sapiens (human) | Potency | 20.7329 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 8.9125 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 1.0000 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 2.8184 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 2.8184 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
| 67.9K protein | Vaccinia virus | Potency | 10.0000 | 0.0001 | 8.4406 | 100.0000 | AID720580 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 39.8107 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 44.6684 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 14.1254 | 0.0366 | 19.6376 | 50.1187 | AID2100 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 20.3865 | 5.8048 | 36.1306 | 65.1308 | AID540253; AID540263 |
| snurportin-1 | Homo sapiens (human) | Potency | 20.3865 | 5.8048 | 36.1306 | 65.1308 | AID540253; AID540263 |
| histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 2.8184 | 0.0103 | 23.8567 | 63.0957 | AID2662 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 31.6228 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 28.1838 | 5.8048 | 16.9962 | 25.9290 | AID540253 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 70.7946 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 8.9125 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 8.9125 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 8.9125 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 14.5015 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
| lethal(3)malignant brain tumor-like protein 1 isoform I | Homo sapiens (human) | Potency | 22.3872 | 0.0752 | 15.2253 | 39.8107 | AID485360 |
| geminin | Homo sapiens (human) | Potency | 23.1093 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
| DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | Potency | 17.0737 | 0.0580 | 10.6949 | 26.6086 | AID602310; AID651812; AID651813 |
| DNA dC->dU-editing enzyme APOBEC-3F isoform a | Homo sapiens (human) | Potency | 15.2903 | 0.0259 | 11.2398 | 31.6228 | AID602313; AID651814; AID651815 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 25.1189 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 35.4813 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 35.4813 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| MPI protein | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.1900 | 13.8256 | 50.1000 | AID1535; AID1536 |
| toll-like receptor 9 | Homo sapiens (human) | IC50 (µMol) | 13.0990 | 1.8690 | 5.4371 | 9.2420 | AID588340 |
| intestinal alkaline phosphatase precursor | Mus musculus (house mouse) | IC50 (µMol) | 8.0900 | 0.2590 | 11.8708 | 60.3000 | AID488874 |
| alkaline phosphatase, germ cell type preproprotein | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.1100 | 11.3862 | 67.2000 | AID1512 |
| Beta lactamase (plasmid) | Pseudomonas aeruginosa | IC50 (µMol) | 11.7980 | 0.7091 | 5.0549 | 7.7510 | AID588341 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| alkaline phosphatase, intestinal | Homo sapiens (human) | EC50 (µMol) | 3.6820 | 0.2570 | 26.8395 | 81.0000 | AID463120; AID488817; AID493132 |
| glutathione S-transferase, partial | Homo sapiens (human) | EC50 (µMol) | 2.3820 | 1.5120 | 15.6244 | 46.8700 | AID1769 |
| alkaline phosphatase, tissue-nonspecific isozyme isoform 1 preproprotein | Homo sapiens (human) | EC50 (µMol) | 0.5678 | 0.2270 | 25.0904 | 86.8000 | AID1001; AID1450; AID1659; AID488886; AID493112 |
| intestinal alkaline phosphatase precursor | Mus musculus (house mouse) | EC50 (µMol) | 0.3820 | 0.3820 | 42.4691 | 75.0000 | AID493128 |
| alkaline phosphatase, germ cell type preproprotein | Homo sapiens (human) | EC50 (µMol) | 0.7100 | 0.5500 | 33.7339 | 74.0000 | AID488888; AID493126 |
| endoribonuclease toxin MazF | Escherichia coli str. K-12 substr. MG1655 | EC50 (µMol) | 86.0500 | 3.9600 | 9.5157 | 17.4000 | AID588481; AID588502 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| heat shock protein HSP 90-alpha isoform 2 | Homo sapiens (human) | AC50 | 3.3420 | 0.1950 | 3.6679 | 18.6960 | AID540270 |
| heat shock protein 90, putative | Plasmodium falciparum 3D7 | AC50 | 1.4620 | 0.1950 | 4.9920 | 98.5000 | AID540268 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||